Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
NCT ID: NCT04079881
Last Updated: 2022-10-07
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
1 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-02-13
Study Completion Date
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence of endogenous insulin secretion results in increased glucagon secretion after a mixed meal, concluding that endogenous insulin reciprocally regulates the alpha-cell glucagon secretion and also suggesting that glucagon dysregulation may play an important role in post-prandial hyperglycemia in T1D. Interestingly, recent research on human islets have shown that insulin inhibits counter-regulatory glucagon secretion by a paracrine effect mediated by SGLT2-dependent stimulation of somatostatin release. An important gap in our knowledge is whether the timing of prandial insulin doses affects the glucagon response to a hyperglycemic stimulus in patients with T1D who have undetectable C-peptide.
Whether appropriately timed exogenous insulin can modify the glucagon response to glucose fluctuations has not been studied. As such, this pilot study aims to characterize the glucagon response to meal-time hyperglycemia and to compare the difference in glucagon secretion when mealtime bolus insulin is given before the meal versus after the meal with the objective of understanding factors that contribute to the peak post-prandial blood glucose and AUC of blood glucose after a mixed meal in this target population.
Whether appropriately timed exogenous insulin can modify the glucagon response to glucose fluctuations has not been studied. As such, this pilot study aims to characterize the glucagon response to meal-time hyperglycemia and to compare the difference in glucagon secretion when mealtime bolus insulin is given before the meal versus after the meal with the objective of understanding factors that contribute to the peak post-prandial blood glucose and AUC of blood glucose after a mixed meal in this target population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiologic Response to Glucagon at Varying Insulin Levels
NCT01483651
Type 1 Diabetes Mellitus
COMPLETED
NA
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT00704795
Hyperglucagonemia
Hyperglycemia
Diabetes Mellitus
UNKNOWN
The Role of Amylin and Glucagon in T1DM
NCT00206258
Type 1 Diabetes
COMPLETED
PHASE3
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
NCT01986231
Type 1 Diabetes Mellitus
COMPLETED
NA
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582
Type 1 Diabetes
UNKNOWN
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence of endogenous insulin secretion results in increased glucagon secretion after a mixed meal , concluding that endogenous insulin reciprocally regulates the alpha-cell glucagon secretion and also suggesting that glucagon dysregulation may play an important role in post-prandial hyperglycemia in T1D. Interestingly, recent research on human islets have shown that insulin inhibits counter-regulatory glucagon secretion by a paracrine effect mediated by SGLT2-dependent stimulation of somatostatin release. An important gap in our knowledge is whether the timing of prandial insulin doses affects the glucagon response to a hyperglycemic stimulus in patients with T1D who have undetectable C-peptide.
T1D course. In general, loss of 80% of beta cell function is needed to develop severe hyperglycemia. Endogenous insulin secretion is almost entirely lost within 3 to 5 years after the diagnosis . In children with new diagnosis of T1D, glucagon levels were highly associated with post prandial blood glucose, but not with HbA1c level. It has also been reported that postprandial hyperglucagonemia worsens significantly while C-peptide secretion declines during the first year of the disease. Also, in children with greater than five years of T1D, postprandial glucagon levels increased 160% from one to sixty months after diagnosis (8) and in those with disease duration of 6.9 + 4 years, glucagon levels were strongly correlated with post-prandial glucose and mildly correlated with HbA1C levels. A study in T1D adults performed in China showed that post-prandial glucagon levels were higher in T1D patients in the first year of the disease compared to those with longer course of the disease, and that hypoglycemic events were lower in newly diagnosed patients, suggesting that glucagon secretory function may become impaired with longer duration of the disease. These studies suggest that glucagon dysregulation could impact glucose control with exogenous insulin, and that this dysregulation may change with disease duration.
Post-prandial hyperglycemia adds to glucose variability, difficulty with insulin dosing and overall instability of glucose control. A recent analysis from the T1D Exchange study, that included 4768 participants younger than 26 years with a clinical diagnosis of T1D for at least 1 year showed that 21% of the participants reported administering insulin several minutes before, 44% immediately before, 10% during, and 24% after meal. Interestingly, participants who reported administering insulin during or after a meal were more likely to report missing ≥1 mealtime insulin dose per week compared with those who administered insulin before meals. In addition, a sub-analysis showed that participants who dose mealtime insulin in the postprandial period have poorer glycemic control and greater frequency of severe hypoglycemia. However, despite of these recent results, patients are often advised to give insulin after eating because caloric intake is uncertain. Understanding the mechanisms behind the higher post-prandial peak in glucose with delayed insulin administration may help clinicians guide appropriate timing of insulin administration for T1D patients with long course of the disease.
Glucagon Regulation:
Different models have been used to study glucagon regulation. Since both hyperglycemia and hypoglycemia stimulate alpha cells to produce glucagon, both the lack of intra-islet insulin and this U-shaped glucagon response contribute to glucose dysregulation in T1D . It has been reported that in T1D patients with a duration of the disease of 26.4+7.5 years, glucagon levels increased in response to the OGTT under euglycemic and hyperglycemic conditions, however the relative contribution of hyperglucagonemia to post-prandial glucose rise in the presence or absence of preprandial insulin has not been clearly elucidated. Whether appropriately timed exogenous insulin can modify the glucagon response to glucose fluctuations has not been studied. As such, this pilot study aims to characterize the glucagon response to meal-time hyperglycemia and to compare the difference in glucagon secretion when mealtime bolus insulin is given before the meal versus after the meal with the objective of understanding factors that contribute to the peak post-prandial blood glucose and AUC of blood glucose after a mixed meal in this target population.
Hypothesis
1. Patients with higher glucagon responses to a mixed meal stimulus will have higher peak post-prandial glucoses and greater AUC of post-prandial glucose.
2. Bolus dose insulin given pre-meal (20 min before meal) will result in lower peak post-prandial glucose, lower AUC and lower post-prandial glucagon levels
3. Bolus dose insulin given post-meal (20 min after meal) will result in higher peak post-prandial glucoses, higher AUC of post-meal glucose and higher glucagon levels
4. There will be a correlation between peak post-prandial glucagon response and post-meal glucose AUC, 0 to 180 minutes.
Research Plans The study will be conducted in the (Intensive Research Unit, part of the CTSA) Diabetes Center at Barnes Jewish Hospital/Washington University in St Louis.
Study Visits
* Screening will be done over the phone and with review of medical records if the required labs have been done in the past 6 months
* Visits A and B will be performed in random order
* Demographics, review of diabetes history, medications and allergies will be recorded at the first study visit. Insulin doses and effectiveness of current carbohydrate ratio will be evaluated and recorded. Mealtime insulin doses will be established at the first study visit.
* Mealtime insulin will be given via injection by a study nurse to standardize the administration procedure.
* Vital signs, height and weight will be done at each visit
* C-peptide will be checked with the fasting labs at the first study visit
* Baseline glucose should be 80 to 140 mg/dl. In case baseline glucose is not in the target range, the study visit will be rescheduled.
* Whole blood will be collected in vacutainers via an indwelling peripheral venous catheter with nursing supervision.
* Samples will be deidentified before sending to the laboratory.
* No genetic testing will be performed.
Visit A
* Glucose levels done fasting, 30, 60, 120, and 180 minutes
* Glucagon levels done fasting, 30, 60, 120, and 180 minutes
* Usual insulin dose will be administered 20 minutes prior to a mixed meal challenge with Ensure Plus\*
Visit B
* Glucose done fasting, 30, 60, 120, and 180 minutes
* Glucagon levels done fasting, 30, 60, 120, and 180 minutes
* Usual insulin dose will be administered 20 minutes after the mixed meal challenge with
Ensure Plus\*
\*Ensure Plus (Abbott Nutrition) at 6cc/kg (max 360 cc), content per 100 ml: carbohydrate 21.5 grams, protein 5.5 grams, with nursing supervision.
Laboratory Measures:
Core Laboratory for Clinical Studies at Washington University (https://research.wustl.edu/core-facilities/core-laboratory-clinical-studies, CLCS) will measure glucose on the Roche cobas c510 platform using Roche's coupled enzymatic assay (hexokinase, glucose-6-phosphoate dehydrogenase). The rate of NADPH formation is directly proportional to glucose concentration and measured photometrically. The interday imprecision is typically \<2.0% CV. CLCS will also measure C-peptide on the Roche cobas e601platform using Roche's sandwich electrochemiluminescence immunoassay. In this assay a biotinylated monoclonal C-peptide-specific antibody and a monoclonal C-peptide-specific antibody labeled with a ruthenium complex bind to C-peptide to form the sandwich. Then, using streptavidin-coated microparticles, the complex is drawn into the measuring cell and remains while unbound material is washed away. Application of a voltage to the electrode induces chemiluminescent emission that is measured by the instrument. Between run precision typically ranges from 1.9 - 2.7% CV.
Glucagon is measured using a radioimmunoassay kit from Millipore. This is a competitive immunoassay which uses I-125 labeled glucagon and a glucagon-specific antibody. Its stated inter-assay precision is 12% CV. Typical within-run precision is 2.0 - 3.0 % CV in our hands.
Methods of Data Analysis Data analysis will be performed using STATA 15.1 for Windows (StataCorp LP, College Station, Texas, United States). The sample size calculation assumes that the peak postprandial glucose will increase by 80 +/-20 mg/dl in the pre-meal insulin group and 140 +/-20 mg/dl in the post-meal group. So, the expected mean peak of postprandial glucose will be up to 220 mg/dL for Visit A and mean peak postprandial glucose will be up to 280 mg/dL for Visit B. The sample size will have 80% power to detect a difference between groups at p\<0.05. We have assumed correlation between visits A and B of 0.5. The sample size was corrected by an anticipated loss of follow up of 10% of the participants. The calculated sample size is 10 participants with full data sets available for 8 participants. The study randomization is designed as follows: 5 participants will first attend Visit A, and then Visit B. The 5 remaining participants will first attend Visit B and then Visit A. AUC of post-prandial glucose and glucagon and maximum postprandial peak of glucose and glucagon will be analyzed by using paired T student. Relationships between variables were assessed by a Spearman's correlation test.
T1D course. In general, loss of 80% of beta cell function is needed to develop severe hyperglycemia. Endogenous insulin secretion is almost entirely lost within 3 to 5 years after the diagnosis . In children with new diagnosis of T1D, glucagon levels were highly associated with post prandial blood glucose, but not with HbA1c level. It has also been reported that postprandial hyperglucagonemia worsens significantly while C-peptide secretion declines during the first year of the disease. Also, in children with greater than five years of T1D, postprandial glucagon levels increased 160% from one to sixty months after diagnosis (8) and in those with disease duration of 6.9 + 4 years, glucagon levels were strongly correlated with post-prandial glucose and mildly correlated with HbA1C levels. A study in T1D adults performed in China showed that post-prandial glucagon levels were higher in T1D patients in the first year of the disease compared to those with longer course of the disease, and that hypoglycemic events were lower in newly diagnosed patients, suggesting that glucagon secretory function may become impaired with longer duration of the disease. These studies suggest that glucagon dysregulation could impact glucose control with exogenous insulin, and that this dysregulation may change with disease duration.
Post-prandial hyperglycemia adds to glucose variability, difficulty with insulin dosing and overall instability of glucose control. A recent analysis from the T1D Exchange study, that included 4768 participants younger than 26 years with a clinical diagnosis of T1D for at least 1 year showed that 21% of the participants reported administering insulin several minutes before, 44% immediately before, 10% during, and 24% after meal. Interestingly, participants who reported administering insulin during or after a meal were more likely to report missing ≥1 mealtime insulin dose per week compared with those who administered insulin before meals. In addition, a sub-analysis showed that participants who dose mealtime insulin in the postprandial period have poorer glycemic control and greater frequency of severe hypoglycemia. However, despite of these recent results, patients are often advised to give insulin after eating because caloric intake is uncertain. Understanding the mechanisms behind the higher post-prandial peak in glucose with delayed insulin administration may help clinicians guide appropriate timing of insulin administration for T1D patients with long course of the disease.
Glucagon Regulation:
Different models have been used to study glucagon regulation. Since both hyperglycemia and hypoglycemia stimulate alpha cells to produce glucagon, both the lack of intra-islet insulin and this U-shaped glucagon response contribute to glucose dysregulation in T1D . It has been reported that in T1D patients with a duration of the disease of 26.4+7.5 years, glucagon levels increased in response to the OGTT under euglycemic and hyperglycemic conditions, however the relative contribution of hyperglucagonemia to post-prandial glucose rise in the presence or absence of preprandial insulin has not been clearly elucidated. Whether appropriately timed exogenous insulin can modify the glucagon response to glucose fluctuations has not been studied. As such, this pilot study aims to characterize the glucagon response to meal-time hyperglycemia and to compare the difference in glucagon secretion when mealtime bolus insulin is given before the meal versus after the meal with the objective of understanding factors that contribute to the peak post-prandial blood glucose and AUC of blood glucose after a mixed meal in this target population.
Hypothesis
1. Patients with higher glucagon responses to a mixed meal stimulus will have higher peak post-prandial glucoses and greater AUC of post-prandial glucose.
2. Bolus dose insulin given pre-meal (20 min before meal) will result in lower peak post-prandial glucose, lower AUC and lower post-prandial glucagon levels
3. Bolus dose insulin given post-meal (20 min after meal) will result in higher peak post-prandial glucoses, higher AUC of post-meal glucose and higher glucagon levels
4. There will be a correlation between peak post-prandial glucagon response and post-meal glucose AUC, 0 to 180 minutes.
Research Plans The study will be conducted in the (Intensive Research Unit, part of the CTSA) Diabetes Center at Barnes Jewish Hospital/Washington University in St Louis.
Study Visits
* Screening will be done over the phone and with review of medical records if the required labs have been done in the past 6 months
* Visits A and B will be performed in random order
* Demographics, review of diabetes history, medications and allergies will be recorded at the first study visit. Insulin doses and effectiveness of current carbohydrate ratio will be evaluated and recorded. Mealtime insulin doses will be established at the first study visit.
* Mealtime insulin will be given via injection by a study nurse to standardize the administration procedure.
* Vital signs, height and weight will be done at each visit
* C-peptide will be checked with the fasting labs at the first study visit
* Baseline glucose should be 80 to 140 mg/dl. In case baseline glucose is not in the target range, the study visit will be rescheduled.
* Whole blood will be collected in vacutainers via an indwelling peripheral venous catheter with nursing supervision.
* Samples will be deidentified before sending to the laboratory.
* No genetic testing will be performed.
Visit A
* Glucose levels done fasting, 30, 60, 120, and 180 minutes
* Glucagon levels done fasting, 30, 60, 120, and 180 minutes
* Usual insulin dose will be administered 20 minutes prior to a mixed meal challenge with Ensure Plus\*
Visit B
* Glucose done fasting, 30, 60, 120, and 180 minutes
* Glucagon levels done fasting, 30, 60, 120, and 180 minutes
* Usual insulin dose will be administered 20 minutes after the mixed meal challenge with
Ensure Plus\*
\*Ensure Plus (Abbott Nutrition) at 6cc/kg (max 360 cc), content per 100 ml: carbohydrate 21.5 grams, protein 5.5 grams, with nursing supervision.
Laboratory Measures:
Core Laboratory for Clinical Studies at Washington University (https://research.wustl.edu/core-facilities/core-laboratory-clinical-studies, CLCS) will measure glucose on the Roche cobas c510 platform using Roche's coupled enzymatic assay (hexokinase, glucose-6-phosphoate dehydrogenase). The rate of NADPH formation is directly proportional to glucose concentration and measured photometrically. The interday imprecision is typically \<2.0% CV. CLCS will also measure C-peptide on the Roche cobas e601platform using Roche's sandwich electrochemiluminescence immunoassay. In this assay a biotinylated monoclonal C-peptide-specific antibody and a monoclonal C-peptide-specific antibody labeled with a ruthenium complex bind to C-peptide to form the sandwich. Then, using streptavidin-coated microparticles, the complex is drawn into the measuring cell and remains while unbound material is washed away. Application of a voltage to the electrode induces chemiluminescent emission that is measured by the instrument. Between run precision typically ranges from 1.9 - 2.7% CV.
Glucagon is measured using a radioimmunoassay kit from Millipore. This is a competitive immunoassay which uses I-125 labeled glucagon and a glucagon-specific antibody. Its stated inter-assay precision is 12% CV. Typical within-run precision is 2.0 - 3.0 % CV in our hands.
Methods of Data Analysis Data analysis will be performed using STATA 15.1 for Windows (StataCorp LP, College Station, Texas, United States). The sample size calculation assumes that the peak postprandial glucose will increase by 80 +/-20 mg/dl in the pre-meal insulin group and 140 +/-20 mg/dl in the post-meal group. So, the expected mean peak of postprandial glucose will be up to 220 mg/dL for Visit A and mean peak postprandial glucose will be up to 280 mg/dL for Visit B. The sample size will have 80% power to detect a difference between groups at p\<0.05. We have assumed correlation between visits A and B of 0.5. The sample size was corrected by an anticipated loss of follow up of 10% of the participants. The calculated sample size is 10 participants with full data sets available for 8 participants. The study randomization is designed as follows: 5 participants will first attend Visit A, and then Visit B. The 5 remaining participants will first attend Visit B and then Visit A. AUC of post-prandial glucose and glucagon and maximum postprandial peak of glucose and glucagon will be analyzed by using paired T student. Relationships between variables were assessed by a Spearman's correlation test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 1 Diabetes
Hyperglycemia, Postprandial
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Participants are randomly assigned receive intervention A then intervention B or to receive intervention B than intervention A
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A (Pre-prandial insulin administration) : B (post-prandial insulin administration)
VISIT 1: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.
Then VISIT 2: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.
Group Type
EXPERIMENTAL
Insulin
Intervention Type
DRUG
to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
B (post-prandial insulin administration) : A (Pre-prandial insulin administration) :b
VISIT 1: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.
Then VISIT 2: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.
Group Type
EXPERIMENTAL
Insulin
Intervention Type
DRUG
to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin
to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Pre-prandial insulin
postprandial insulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10 persons with T1D for \>5 years age \>18.
* HbA1c \<9.5%
* Patients using either MDI or insulin pumps will be included.
* Patients using CGM will continue the use during the study, however glucoses will be measured by laboratory methods.
* Persons of all races, ethnicity and genders will be included
* Participants should have normal hemoglobin, hematocrit and eGFR \>60 ml/min/1.73m2.
* HbA1c \<9.5%
* Patients using either MDI or insulin pumps will be included.
* Patients using CGM will continue the use during the study, however glucoses will be measured by laboratory methods.
* Persons of all races, ethnicity and genders will be included
* Participants should have normal hemoglobin, hematocrit and eGFR \>60 ml/min/1.73m2.
Exclusion Criteria
* Persons with type 2 diabetes, monogenic diabetes, pancreatic diseases.
* Pregnancy, prisoners, other vulnerable populations or persons unable to understand the protocol and provide written informed consent.
* Persons who take daily steroids, any route, for any purpose
* Pregnancy, prisoners, other vulnerable populations or persons unable to understand the protocol and provide written informed consent.
* Persons who take daily steroids, any route, for any purpose
Minimum Eligible Age
18 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet McGill, MD
Role: PRINCIPAL_INVESTIGATOR
Wash. Univ. School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington University in St Louis
St Louis, Missouri, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13.
Reference Type
BACKGROUND
Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010 Nov;59(11):2936-40. doi: 10.2337/db10-0728. Epub 2010 Aug 23.
Reference Type
BACKGROUND
Vergari E, Knudsen JG, Ramracheya R, Salehi A, Zhang Q, Adam J, Asterholm IW, Benrick A, Briant LJB, Chibalina MV, Gribble FM, Hamilton A, Hastoy B, Reimann F, Rorsman NJG, Spiliotis II, Tarasov A, Wu Y, Ashcroft FM, Rorsman P. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 2019 Jan 11;10(1):139. doi: 10.1038/s41467-018-08193-8.
Reference Type
BACKGROUND
Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D. Factors predicting course of beta-cell function in IDDM. Diabetes Care. 1992 Aug;15(8):997-1001. doi: 10.2337/diacare.15.8.997.
Reference Type
BACKGROUND
Yosten GLC. Alpha cell dysfunction in type 1 diabetes. Peptides. 2018 Feb;100:54-60. doi: 10.1016/j.peptides.2017.12.001.
Reference Type
BACKGROUND
Porksen S, Nielsen LB, Kaas A, Kocova M, Chiarelli F, Orskov C, Holst JJ, Ploug KB, Hougaard P, Hansen L, Mortensen HB; Hvidore Study Group on Childhood Diabetes. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab. 2007 Aug;92(8):2910-6. doi: 10.1210/jc.2007-0244. Epub 2007 May 22.
Reference Type
BACKGROUND
Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care. 2008 Jul;31(7):1403-4. doi: 10.2337/dc08-0575.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201909013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults
NCT04730882
COMPLETED
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
NCT02882737
COMPLETED
NA
Glucagon Modulation of Ghrelin Secretion
NCT00929812
UNKNOWN
PHASE3
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
NCT02010827
COMPLETED
Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1
NCT05960565
TERMINATED
PHASE2
Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
NCT05076292
COMPLETED
NA
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657
COMPLETED
PHASE3
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
NCT06424106
RECRUITING
NA
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098
COMPLETED
NA
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
NCT06881472
ACTIVE_NOT_RECRUITING
NA
Glucagon Counterregulation in Type 1 Diabetes
NCT03547427
TERMINATED
NA
Very Low Carbohydrate Diets and Glucagon Response in T1DM
NCT04200391
RECRUITING
NA
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
NCT04461015
COMPLETED
PHASE3
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445
COMPLETED
NA
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus
NCT00832741
COMPLETED
Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
NCT05379686
COMPLETED
NA
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922
WITHDRAWN
EARLY_PHASE1
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
NCT05616273
COMPLETED
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
NCT05007977
TERMINATED
PHASE1
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603
UNKNOWN
NA
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
NCT04300049
COMPLETED
EARLY_PHASE1
Studies of Insulin and Glucagon Action in the Liver
NCT07300982
NOT_YET_RECRUITING
PHASE1/PHASE2
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
NCT00993720
COMPLETED
PHASE2/PHASE3
Glucagon Efficiency After High and Low Carbohydrate Diet
NCT02578498
COMPLETED
PHASE4
Postprandial Gut Hormone Responses in Patients With Type 1 Diabetes Mellitus
NCT04430946
UNKNOWN
NA